Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185

International Journal of Cancer

Volumn 82, Issue 4, 1999, Pages 525-531

  Boyer, Cinda M ^a   Pusztai, Lajos ^b   Wiener, Jon R ^b   Xu, Feng Ji ^b   Dean, G Scott ^a   Bast, Blanche S ^a   O'Briant, Kathy C ^a   Greenwald, Marilee ^a   DeSombre, Karen A ^a   Bast Jr , Robert C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GENE PRODUCT; IMMUNOTOXIN; PROTEIN P185; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CLONOGENIC ASSAY; DRUG CYTOTOXICITY; EPITOPE MAPPING; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; INTERNALIZATION; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIOIMMUNOASSAY;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; MICE; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; SEQUENCE DELETION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032856715     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990812)82:4<525::AID-IJC10>3.0.CO;2-J     Document Type: Article

References (23)

1. BATRA, J.K., KASPRZYK, P.G., BIRD, R.E., PASTAN, I. and KING, C.R., Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. nat. Acad. Sci. (Wash.), 89, 5867-5871 (1992).
2. BERCHUCK, A. and 12 OTHERS, Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50, 4087-4091 (1990).
3. BOYER, C.M., DAWSON, D.V., NEAL, S.E., WINCHELL, L.F., LESLIE, D.S., RING, D. and BAST, R.C., JR., Differential induction by interferons of major histocompalibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res., 49, 2928-2934 (1989).
4. COBLEIGH, M.A., VOGEL, C.L. and TRIPATHY, D., Efficacy and safety of Herceptin (humanized anti-HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastastic breast cancer. Proc. Amer. Soc. clin. Oncol., 17, 97a (1998).
5. DI FIORE, P.P., PIERCE, J.H., KRAUS, M.H., SEGATTO, O., KING, C.R. and AARONSON, S.A., ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-182 (1987).
6. DREBIN, J.A., LINK, V.C. and GREENE, M.I., Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene, 2, 387-394 (1988).
7. HUDZIAK, R.M., LEWIS, G.D., WINGET, M., FENDLY, B.M., SHEPARD, H.M. and ULLRICH, A., p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. cell. Biol., 9, 1165-1172 (1989).
8. KASPRZYK, P.G., SONG, S.U., DI FIORE, P.P. and KING, C.R., Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res., 52, 2771-2776 (1992).
9. LEWIS-PHILLIPS, G.D., MCMURTREY, A.E., SCHROEDER, K. and FENDLY, B.M., Diverse activities of anti-HER-2 monoclonal antibodies: from growth inhibition to induction of apoptosis. Proc. Amer. Assoc. Cancer Res., 39, 143 (1998).
10. MASUI, H., KAMRATH, H., APELL, G., HOUSTON, L.L. and MENDELSOHN, J., Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res., 49, 3482-3488 (1989).
11. MAY, R.D., FINKELMAN, F.D., WHEELER, H.T., UHR, J.W. and VITETTA, E.S., Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells. J. Immunol., 144, 3637-3642 (1990).
12. MCKENZIE, S.J., MARKS, P.J., LAM, T., MORGAN, J., PANICALI, D.L., TRIMPE, K.L. and CARNEY, W.P., Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p 185. Oncogene, 4, 543-548 (1989).
13. MCPHERSON, G.A., Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J. pharmacol. Meth., 14, 213-228 (1985).
14. ORLANDI, R., FORMANTICI, C., MÉNARD, S., BOYER, C.M., WIENER, J.R. and COLNAGHI, M., A linear region of a monoclonal antibody conformational epitope mapped on p185HER2 oncoprotein. Biol. Chem., 378, 1387-1392 (1997).
15. PRESS, O.W., MARTIN, P.J., THORPE, P.E. and VITETTA, E.S., Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J. Immunol., 141, 4410-4417 (1988).
16. RING, D.B., CLARK, R. and SAXENA, A., Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol. Immunol., 28, 915-917 (1991).
17. RODRIGUEZ, G.C., BOENTE, M.P., BERCHUCK, A., WHITAKER, R.S., O'BRIANT, K.C., XU, F. and BAST, R.C., JR., The effect of antibodies and immunotoxins reactive with Her-2/neu on growth of ovarian and breast cancer cell lines. Amer. J. Obstet. Gynecol., 168, 228-232 (1993).
18. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.G., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J., ULLRICH, A. and PRESS, M.F., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
19. SLAMON, D., LEYLAND-JONES, B., SHAK, S., et al., Addition of Herceptin (Humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Amer. Soc. clin. Oncol., 17, 97a (1998).
20. TAGLIABUE, E., CENTIS, F., CAMPIGLIO, M., MASTROIANNI, A., MARTIGNONE, S., PELLEGRINI, R., CASALINI, P., LANZI, C., MÉNARD, S. and COLNAGHI, M.I., Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/ NEU gene amplification. Int. J. Cancer, 47, 933-937 (1991).
21. TECCE, R., DIGEISI, G., SAVARESE, A., TRIZIO, D. and NATALI, P.G., Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. Int. J. Cancer, 55, 122-127 (1993).
22. WAWRZYNCZAK, E.J. and THORPE, P.E., Methods for preparing immunotoxins: effect of the linkage on activity and stability. In: C.W. Vogel (ed.), Immunoconjugates. Antibody conjugates in radioimaging and therapy of cancer, pp. 28-55, Oxford University Press, New York (1987).
23. XU, F.J., LUPU, R., RODRIGUEZ, G.C., WHITAKER, R.S., BOENTE, M.P., BERCHUCK, A., YU, Y., DESOMBRE, K.A., BOYER, C. and BAST, R.C., JR., Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2) gene product p185. Int. J. Cancer, 53, 401-408 (1993).